SNAP-8 Research

SNAP-8 is a trade name for acetyl octapeptide-3, a synthetic peptide sold as a cosmetic raw material. SNAP-8 is a research compound, not approved for any therapeutic use and not for human consumption. Its independent evidence base is not thin. It is absent. A PubMed search for the ingredient name returns two papers, and neither tests it on its own ^[8]. ClinicalTrials.gov returns zero studies for it across three search terms, and six for the sibling hexapeptide Argireline ^[9].

Molecular identity

Acetyl octapeptide-3 is Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, written Ac-EEMQRRAD-NH2. It is an eight-residue synthetic peptide, acetylated at the N-terminus and amidated at the C-terminus. CAS 868844-74-0 resolves on PubChem to exactly one record, CID 76283482 ^[1]. That record gives C41H70N16O16S and a molecular weight of 1075.2, and both correspond to that sequence ^[1].

Searching the trade name SNAP-8 instead lands on CID 71587832, which carries the same ingredient name and the same FDA unique ingredient identifier ^[1]. Its formula and weight do not correspond to Ac-EEMQRRAD-NH2, because one peptide bond in the deposited structure is drawn as a carbon-carbon double bond ^[1]. That record carries no CAS number ^[1]. The two records therefore carry different formulas for the same ingredient name, and only the record reached through the CAS matches the sequence ^[1].

Acetyl octapeptide-1, acetyl octapeptide-8, acetyl glutamyl heptapeptide-3 and acetyl glutamyl octapeptide-3 are all synonyms of CID 76283482 ^[1]. Acetyl hexapeptide-3 and acetyl hexapeptide-8, by contrast, are two names for Argireline, a shorter and different molecule ^[1][2].

Mechanism is proposed, not demonstrated

SNAP-8 is marketed by analogy to botulinum toxin. Botulinum neurotoxin type A is a bacterial enzyme of roughly 150 kilodaltons, injected into muscle, that catalytically and irreversibly cleaves SNAP-25. Acetyl octapeptide-3 is a synthetic peptide of about 1.1 kilodaltons applied to the skin surface. It is proposed to compete non-catalytically for SNARE complex assembly. They share a protein name, not a route, a size class or an evidence base.

No indexed publication shows acetyl octapeptide-3 interfering with SNARE assembly, inhibiting neurotransmitter release, or reducing muscle contraction ^[8]. Botulinum toxin's clinical results, approvals and safety warnings are not evidence for this peptide, and they are not risks established for it either.

The mechanism story originates in a 2002 study of the hexapeptide Argireline ^[2]. Its in vitro work reported inhibition of neurotransmitter release with much lower efficacy than botulinum toxin A, attributed to interference with SNARE complex formation ^[2]. It also carried a small uncontrolled human skin-topography arm ^[2]. A separate in silico modeling study of peptides designed to mimic botulinum toxin reports binding to synaptotagmin-1 ^[3]. It presents its result as a plausible route rather than a demonstrated one, and it ran no wet-lab assay ^[3].

What the human record for SNAP-8 contains

Four published human studies include acetyl octapeptide-3, and none can attribute an effect to it. Two of the four are returned by a PubMed search on the ingredient name ^[8]. The other two name it only in their full text, which is why the search count and the study count differ ^[8]. A fifth human dataset containing acetyl octapeptide-3 has never been published. It is the trademark holder's in-house comparison of this peptide against its own earlier peptide, and it is the only ingredient-level human comparison in existence.

The strongest by design is a split-face, placebo-controlled human study in 24 healthy subjects, using a dissolving microneedle patch over 28 days ^[4]. The active patch carried three actives, and the placebo patch carried the hyaluronic acid backbone alone ^[4]. Improvements in eye wrinkles, transepidermal water loss and elasticity were reported, with no adverse effects ^[4]. Because the comparator omitted all three actives, the design cannot separate this peptide from the other two or from the microneedle delivery itself ^[4].

A second human study followed a five-active microneedle patch for 12 weeks, single-arm and uncontrolled ^[5]. It reported reductions in fine lines and improvements in hydration and dermal density ^[5]. Its own authors state only that the ingredients might act together ^[5]. Enrollment is not reported in the abstract or in the indexed metadata ^[5].

The remaining two human studies were monadic, with no control arm and no placebo ^[6][7]. One ran 24 weeks in 50 enrolled women, of whom 47 completed ^[6]. The other paired ex vivo skin explant work with a 12-week whole-face study of a proprietary serum ^[7]. The acetyl octapeptide-3 concentration in that proprietary serum is not disclosed ^[7].

Both patch studies delivered the peptide by physically puncturing the stratum corneum ^[4][5]. That route bypasses the barrier that is the open question for this class.

SNAP-8 and skin permeation

No skin-permeation, skin-penetration or percutaneous-absorption study of acetyl octapeptide-3 has been published ^[8]. The only unfunded, independent assessment in this area is a 2025 review of the sibling hexapeptide ^[10]. It reports that the hexapeptide reaches epidermal layers but has a low chance of penetrating the dermis ^[10]. It concludes that transdermal delivery sufficient to paralyze muscle is likely impossible ^[10]. The permeation estimates it summarizes are widely discordant ^[10]. In the study at the low end, almost all of the applied peptide was recovered from the skin surface rather than from within the skin ^[10]. The review also states that none of the in vivo application studies it covers confirmed an inhibitory effect on muscle contraction or a role in smoothing wrinkles ^[10].

That review does not mention acetyl octapeptide-3 or SNAP-8 anywhere ^[10]. Its findings are therefore findings about the hexapeptide, not about this molecule. Acetyl octapeptide-3 is the heavier of the two and carries two additional residues, one of them acidic ^[1]. On structural grounds it is the poorer candidate for skin permeation. That inference comes from structure, not from measurement.

Regulatory status and the records that resemble approvals

No drug approval for acetyl octapeptide-3 exists, and no drug application has been filed, withdrawn or refused ^[9][11]. Field-qualified openFDA searches on substance name return no match against the drug label database or Drugs@FDA ^[11]. Several registry records nonetheless read like approvals.

An unqualified openFDA label search returns 46 records, of which 40 carry the peptide in the inactive-ingredient field and 13 have no sunscreen active at all ^[11]. One is a self-published over-the-counter label naming the peptide an active ingredient, under the marketing category unapproved drug other ^[11]. FDA's NDC directory separately lists two bulk-ingredient registrations under the name SNAP-8 ^[12]. A drug listing is a registration made by the lister, not an approval ^[12].

FDA's substance registry shows the identifier record with a status of approved, which is a record-curation state ^[11]. NCATS Inxight Drugs shows a 2012 status under 21 CFR 352, the over-the-counter sunscreen monograph ^[11]. That status attaches to finished sunscreens in which the peptide is an excipient ^[11]. RxNorm carries an ingredient concept record for the peptide, which is a naming identifier rather than a marketing authorization ^[15].

In the EU the ingredient is listed in the CosIng inventory under Regulation (EC) 1223/2009 ^[13]. That listing records that a name and a declared function exist ^[13]. It is not a pre-market approval, a safety finding or an efficacy finding ^[13].

The Cosmetic Ingredient Review has never assessed acetyl octapeptide-3 ^[14]. The report that search engines surface for searches on this ingredient is a draft on acetyl hexapeptide-8 ^[14]. Its conclusion section reads, in that draft's own words, "To be determined…" ^[14].

Safety data, and the absence of scrutiny

No systemic, oral, repeat-dose, genotoxicity, sensitization or reproductive toxicity study on acetyl octapeptide-3 has been published ^[8]. The tolerability statements that exist are observations from the two multi-ingredient patch studies in humans, without systemic monitoring ^[4][5]. That is the whole safety database. A statement that no in vivo oral toxicity and no primary irritation were found also circulates on retail pages for this ingredient. That statement comes from the 2002 Argireline paper and describes a different molecule ^[2][8].

No trial has been halted and no application refused for this ingredient ^[9][11]. That is because no regulated development program was ever opened. Absence of a negative finding here reflects absence of looking.

The entire published record for this molecule is topical or microneedle application ^[8]. No human or animal data on injection, on any systemic route, or on pharmacokinetics has been published ^[8].

Conflicts of interest in the literature

Every human dataset containing acetyl octapeptide-3 was produced by a party with a commercial interest in the result. Four of the five authors of the split-face patch study are employed by the patch manufacturer ^[4]. That paper states that the authors have nothing to disclose ^[4]. The 12-week patch study records funding from a company that is also the affiliation of three of five authors and the maker of the product ^[5]. Both monadic studies were written by employees, and one by a declared paid consultant, of the company whose product was tested ^[6][7].

The head-to-head efficacy comparison behind most retail claims is an unpublished in-house human study by the trademark holder, set against its own earlier peptide. It carries no PMID, no DOI, no journal and no registration, and no primary document for it could be located. A separate wrinkle-reduction percentage circulating on vendor pages traces to no primary document and contradicts the manufacturer's own figure.

That comparison also used a solution far more concentrated than the levels reported for the sibling peptide in finished cosmetic products ^[14]. No dose-response study for acetyl octapeptide-3 was located in the indexed literature ^[8].

Conclusion

The identity chemistry of acetyl octapeptide-3 is sound and independently reproducible ^[1]. The mechanism is an analogy borrowed from a different peptide, never demonstrated for this one ^[2][8]. The four published human studies test products, not the ingredient ^[4][5][6][7]. The only human comparison of the ingredient itself is unpublished manufacturer data. The positive results on this ingredient come from sellers, and the one unfunded, independent assessment of skin permeation in this class is negative and about another molecule ^[10]. SNAP-8 is a research compound.

Frequently Asked Questions

How much human evidence exists for acetyl octapeptide-3 specifically?

A PubMed search on the ingredient name returns two papers, and neither tests it on its own ^[8]. Two further published human studies name it only in their full text, and both are multi-ingredient products with no control arm ^[6][7][8]. A fifth human dataset, the trademark holder's own comparison, has never been published. ClinicalTrials.gov returns zero studies across three search terms, and six for the sibling hexapeptide Argireline ^[9].

Is SNAP-8 the same compound as Argireline?

No. Argireline is the hexapeptide acetyl hexapeptide-8, a shorter and different molecule ^[1][2]. SNAP-8 is acetyl octapeptide-3, Ac-EEMQRRAD-NH2 ^[1]. Acetyl hexapeptide-3 and acetyl hexapeptide-8 are two names for that same hexapeptide ^[1].

Does SNAP-8 work the way botulinum toxin does?

The comparison is a marketing analogy about a shared protein target, not a transfer of evidence. No indexed publication shows acetyl octapeptide-3 interfering with SNARE assembly or reducing muscle contraction ^[8]. Botulinum toxin's clinical results, approvals and safety warnings belong to botulinum toxin and are not established for this peptide.

Is acetyl octapeptide-3 approved by any regulator?

No drug approval exists, and field-qualified openFDA searches return no record ^[11]. Its EU CosIng entry is an inventory listing, not a pre-market approval ^[13]. The bulk-ingredient NDC registrations, the substance registry's approved status and the RxNorm ingredient concept are registry states rather than approvals ^[11][12][15].

References

1. 1

   NCBI PubChem. Compound record CID 76283482; CAS 868844-74-0. PUG-REST, queried 2026-08-28. CAS round-tripped to a single CID; MolecularFormula C41H70N16O16S, MolecularWeight 1075.2; synonyms include Ac-glu-glu-met-gln-arg-arg-ala-asp-nh2, Acetyl octapeptide-1, Acetyl Octapeptide-8, Acetyl Glutamyl Heptapeptide-3, Acetyl Glutamyl Octapeptide-3, UNII 8K14HJF88S. Name lookup for "SNAP-8" returns a different record, CID 71587832, which carries no CAS and a formula that does not correspond to Ac-EEMQRRAD-NH2; its isomeric SMILES contains the fragment NC(=C) in place of an amide NC(=O), confirming the deposition error directly. The sibling record CID 71587772 corresponds to acetyl hexapeptide-8 / Argireline and carries the same class of error.
2. 2

   Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002 Oct;24(5):303-10. PMID 18498523. DOI: 10.1046/j.1467-2494.2002.00153.x (in vitro mechanism plus a small uncontrolled human skin-topography arm; the subject is Argireline, not acetyl octapeptide-3)
3. 3

   Wongrattanakamon P, et al. Molecular modeling elucidates the cellular mechanism of synaptotagmin-SNARE inhibition: a novel plausible route to design botox-like peptides. Mol Cell Biochem. 2018 May;442(1-2):97-109. PMID 29019108. DOI: 10.1007/s11010-017-3196-5 (in silico modeling and molecular dynamics only)
4. 4

   Shin JY, Han D, Yoon KY, Jeong DH, Park YI. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Ann Dermatol. 2024 Aug;36(4):215-224. PMID 39082657. PMCID: PMC11291098. DOI: 10.5021/ad.23.136 (split-face placebo-controlled human study, n=24; three-active patch versus hyaluronic-acid-only placebo patch)
5. 5

   Avcil M, Akman G, Klokkers J, Jeong D, Çelik A. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. J Cosmet Dermatol. 2020 Feb;19(2):328-337. PMID 31134751. DOI: 10.1111/jocd.13009 (single-arm uncontrolled human study of a five-active patch; enrollment not reported in the abstract or in Europe PMC core metadata)
6. 6

   Draelos ZD, Diaz I. The Benefits of a Multimechanistic Antiaging Skin Technology. Dermatol Ther (Heidelb). 2023 Dec;13(12):3111-3119. PMID 37861918. PMCID: PMC10689314. DOI: 10.1007/s13555-023-01055-2 (monadic 24-week human use study; declared COI: Draelos is a paid Colgate-Palmolive consultant and researcher, Diaz is a Colgate-Palmolive employee)
7. 7

   Moy M, Diaz I, Lesniak E, Giancola G. Peptide-pro complex serum: Investigating effects on aged skin. J Cosmet Dermatol. 2023 Jan;22(1):267-274. PMID 35426243. PMCID: PMC10084013. DOI: 10.1111/jocd.14992 (ex vivo explant work plus a monadic 12-week human study; declared COI: all four authors are Colgate-Palmolive employees)
8. 8

   NCBI PubMed literature sweep. E-utilities esearch, re-run 2026-08-28. Term "acetyl octapeptide-3" returns 2 records (PMIDs 39082657, 31134751); the quoted stem "octapeptide-3" returns the same 2; "EEMQRRAD" returns 0; "Ac-EEMQRRAD" returns 0. No record reports SNARE-assembly, neurotransmitter-release, muscle-contraction, skin-permeation, toxicology, pharmacokinetic or dose-response data for acetyl octapeptide-3. Scope: PubMed only. These are absence-of-publication findings, not absence-of-data findings. Europe PMC full-text retrieval on 2026-08-28 confirms that acetyl octapeptide-3 appears in the body text of PMC10689314 and PMC10084013, neither of which the PubMed name search returns; that is why four published human studies contain the ingredient while the search count is two.
9. 9

   ClinicalTrials.gov API v2, countTotal=true, queried 2026-08-28. totalCount = 0 for "acetyl octapeptide-3", 0 for "SNAP-8" and 0 for "acetyl octapeptide". The same API returns totalCount = 6 for both "acetyl hexapeptide-8" and "argireline".
10. 10

    Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals - A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025 Jun 14;26(12):5722. PMID 40565185. PMCID: PMC12193160. DOI: 10.3390/ijms26125722 (review of the sibling hexapeptide; funding statement "This research received no external funding"; no conflicts declared; full text retrieved from Europe PMC and checked 2026-08-28, containing zero occurrences of "octapeptide" or "SNAP-8")
11. 11

    US Food and Drug Administration. openFDA drug/label and drug/drugsfda APIs, queried 2026-08-28 (data last updated 2026-08-27). Field-qualified openfda.substance_name:"ACETYL OCTAPEPTIDE-3" returns NOT_FOUND against both endpoints. The unqualified label search returns 46 records; 40 carry the peptide in the inactive-ingredient field, 13 have no sunscreen active, and 38 have an empty openfda block. SPL id d10c2130-a0e4-0bf3-e053-2995a90a7947 lists it as an active ingredient with purpose "Instant Anti-Puffiness"; the corresponding DailyMed SPL (setid d10c2130-a0e3-0bf3-e053-2995a90a7947) is a HUMAN OTC DRUG LABEL with marketing category "unapproved drug other" and codes the peptide classCode ACTIB. Registry records: FDA GSRS UNII 8K14HJF88S, status "approved" (record-curation state); NCATS Inxight Drugs, 21 CFR 352 status dated 2012.
12. 12

    US Food and Drug Administration. NDC directory, api.fda.gov/drug/ndc.json, active_ingredients.name:"ACETYL OCTAPEPTIDE-3", queried 2026-08-28. Two records, both generic_name "SNAP-8", both marketing category BULK INGREDIENT, both finished=false: product_ndc 73212-071 (Qingdao Biopeptek Co., Ltd., marketing start 2023-04-17) and 83589-154 (Nanjing Chengong Pharmaceutical Co., Ltd., marketing start 2026-02-25).
13. 13

    European Commission. CosIng cosmetic ingredient database, INCI name ACETYL OCTAPEPTIDE-3, under Regulation (EC) No 1223/2009. The primary CosIng record could not be retrieved directly on 2026-08-28, and the listing is reported here from secondary regulatory databases rather than from the CosIng page itself.
14. 14

    Cosmetic Ingredient Review. Safety Assessment of Acetyl Hexapeptide-8 and Acetyl Hexapeptide-8 Amide as Used in Cosmetics. Draft Report for Panel Review, released 2020-08-21, panel date 2020-09-14/15, prepared by Wilbur Johnson Jr. Watermarked "Distributed for Comment Only". Full text, 24 pages: zero occurrences of "octapeptide" or "SNAP-8"; the conclusion section reads "To be determined…". Also the source of the reported in-market use-concentration range for the sibling hexapeptide.
15. 15

    US National Library of Medicine. RxNorm ingredient concept record for acetyl octapeptide-3. An RxNorm concept is a normalized naming record for an ingredient, not a marketing authorization.